Overview

Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
In this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with supratentorial brain tumors 80 patients will be investigated. Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided resections in children and adolescents with supratentorial, intra-axial brain tumors. Secondary objectives are - to determine whether fluorescent tissue truly signifies tumor (positive predictive value) in various pediatric brain tumors - to determine the degree of tumor resection on early post-operative MRI - and to determine the pharmacokinetics of 5-ALA in this population.
Phase:
Phase 2
Details
Lead Sponsor:
Westfälische Wilhelms-Universität Münster
Collaborators:
medac GmbH
photonamic GmbH & Co. KG
Treatments:
Aminolevulinic Acid